Posted by Michael Wonder on 14 May 2020
Swissmedic approves Carbetocin Ferring for the prevention of postpartum haemorrhage in all births
13 May 2020 - Carbetocin Ferring is the first medicine approved under the new Swissmedic and Marketing Authorisation for Global Health Products (MAGHP) procedure, which aims to build capacity and speed up access to essential medicines in low- and middle-income countries.
Ferring Pharmaceuticals today welcomes the Swissmedic approval of Carbetocin Ferring, a heat-stable formulation of carbetocin, for the prevention of excessive bleeding after childbirth following all births, both vaginal and caesarean section.
